Calcitonin: a non-invasive giant cells therapy.
This paper reports four cases of central giant cell granuloma (CGCG) treated with calcitonin, attesting the efficacy and safety of its use as the chosen therapy for large CGCG. Four patients presenting CGCG treated with calcitonin were included in this study. Salmon calcitonin was administered for 6-28 months. It was observed determination of clear lesion limits for surgery, reduction and limitation of lesions. In aggressive cases, the calcitonin therapy was an excellent option, since it does not harm the patient, and a far less aggressive, complementary surgery may be performed in certain cases, avoiding life-long sequelae.
Borges
Hedelson Odenir Iecher
HO
Postgraduate Program in Oral and Maxillofacial Surgery of the College of Dentistry of Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Brazil. hedelson@gmail.com
Machado
Rosilene Andrea
RA
Vidor
Michele Machado
MM
Beltrão
Rodrigo Gomes
RG
Heitz
Cláiton
C
Filho
Manoel Sant'ana
MS
D000293:Adolescent; D000328:Adult; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002116:Calcitonin / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006101:Granuloma, Giant Cell / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D007571:Jaw Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D011859:Radiography
D050071:Bone Density Conservation Agents; C028815:salmon calcitonin; D002116:Calcitonin